The anti-HIgG(Fc)Fab-N-DM1 ADC represents a novel class of antibody-drug conjugates (ADCs) designed for targeted cancer therapy. This ADC utilizes an anti-HIgG(Fc) antibody fragment (Fab) linked to the cytotoxic agent DM1, a potent microtubule inhibitor. By specifically targeting the Fc region of human immunoglobulin G (IgG), the anti-HIgG(Fc)Fab-N-DM1 ADC selectively delivers the cytotoxic payload to tumor cells exhibiting Fc receptors, minimizing off-target effects and enhancing therapeutic efficacy. This targeted approach holds promise for improving outcomes in patients with Fc receptor-expressing tumors, illustrating the potential of precision medicine in oncology.
البحث
Liên Hệ Quảng Cáo
الأقسام
- Nghệ thuật
- Khiếu nại và Tố cáo
- Lắp ráp và Chế tạo
- Khiêu vũ
- Nước uống
- Phim ảnh
- Tài năng
- Đồ ăn
- Trò chơi và Đồ chơi
- Vườn và Trại
- Sức khỏe
- Bất động sản
- Văn học
- Âm nhạc
- Mạng lưới
- أخرى
- Bữa tiệc
- Tôn giáo
- Mua sắm
- Thể thao
- Rạp phim
- Dịch vụ
إقرأ المزيد
The Global Lightweight Aggregates Market till 2032
The global Lightweight Aggregates market is a dynamic and promising industry that has shown...
Case Study: How Businesses Are Leveraging QR Codes for Google Reviews to Drive Growth
In today’s highly competitive market, businesses are constantly seeking new ways to attract...
Six Nations - England Injury Woes Deepen
The strain in Ben Cohen's thigh muscle has added to England's growing list of injuries ahead of...
Dominate the Crypto Market with Cutting-Edge Crypto Exchange Development
The cryptocurrency market is evolving at a rapid pace, with new exchanges emerging to cater to...
Property Management Market to Partake Significant Development during 2024 - 2032
Market Overview:
The Property Management Market encompasses a wide range of services aimed at...